Oxford Vaccine Faces More Questions After AstraZeneca Admits Error

Oxford Vaccine Faces More Questions After AstraZeneca Admits Error

ndtv.com

AstraZeneca faces more vaccine questions after manufacturing error. (Representational)

AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.

While an announcement Monday by Astra and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the UK partners have sparked worries about whether regulators would clear it. In a later statement, Oxford said a difference in manufacturing processes led to some participants being given a half dose instead of a full one.

Astra and Oxford said their vaccine was 90% effective when a half-dose was given before a full-dose booster, and that two full doses showed an efficacy of 62%. But the head of the US vaccine program known as Operation Warp Speed said the next day that the dose showing the higher level of effectiveness was tested in a younger population, and that the half-dose was given to some people because of an error in the quantity of vaccine put into some vials. None of this was disclosed in Astra's original statement.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

96034461

Cases

68506510

Recovered

2052150

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019